The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Dorofeev D.A.
Municipal Clinical Hospital No. 2, Outpatient Department No. 1
Vitkov A.A.
Research Institute of Eye Diseases
Gorobets A.V.
Center of Additional Education;
South Ural State University (SRU) — Institute of Natural and Precise Sciences
Eskova M.V.
Municipal Clinical Hospital No. 2, Outpatient Department No. 1
Efimova K.A.
Municipal Clinical Hospital No. 2, Outpatient Department No. 1
Kanafin E.V.
South Ural State University (SRU) — Institute of Natural and Precise Sciences
Kirilik E.V.
Polyclinic No 1 of the City Clinical Hospital No. 2
Lukyanova K.O.
Municipal Clinical Hospital No. 2, Outpatient Department No. 1
Effectiveness and safety of a hypotensive preservative-free drug in long-term therapy of glaucoma
Journal: Russian Annals of Ophthalmology. 2022;138(5): 66‑72
Views: 1545
Downloaded: 46
To cite this article:
Dorofeev DA, Vitkov AA, Gorobets AV, et al. . Effectiveness and safety of a hypotensive preservative-free drug in long-term therapy of glaucoma. Russian Annals of Ophthalmology.
2022;138(5):66‑72. (In Russ.)
https://doi.org/10.17116/oftalma202213805166
To investigate the condition of the ocular surface and the effectiveness of Taflotan for long-term therapy in patients with newly diagnosed primary open-angle glaucoma in real clinical practice.
This publication presents data form a retrospective observational study that analyzed newly diagnosed glaucoma patients that have been using 1 drop/day of Taflotan in the evening for 12 months. All patients were examined at baseline, and after 1 month and 12 months of treatment, recording intraocular pressure (IOP), retinal photosensitivity indicators (MD, PSD), thickness of the retinal nerve fiber layer (RNFL), and assessing the condition of the ocular surface by Schirmer test, tear breakup time (TBUT), ocular surface disease index (OSDI) questionnaire, as well as measurement of the lacrimal meniscus height and corneal staining with lissamine green.
IOP effectively decreased in all patients using Taflotan, reaching the target pressure by 1 month after therapy initiation. IOP decreased from 25±4 mm Hg at baseline to 17±3mm Hg after 1 month with further decrease down to 16±3 mm Hg after 12 months of therapy. Retinal photosensitivity (MD and PSD) and RNFL thickness did not differ from baseline, and correlated to glaucoma stage. The indicators of the condition of the ocular surface had no significant differences between the baseline, 1-month and 12-month time points.
Taflotan effectively decreases IOP in newly diagnosed glaucoma patients, maintains stable automated perimetry indices and RNFL thickness, and does not affect the ocular surface throughout 12 months of therapy.
Keywords:
Authors:
Dorofeev D.A.
Municipal Clinical Hospital No. 2, Outpatient Department No. 1
Vitkov A.A.
Research Institute of Eye Diseases
Gorobets A.V.
Center of Additional Education;
South Ural State University (SRU) — Institute of Natural and Precise Sciences
Eskova M.V.
Municipal Clinical Hospital No. 2, Outpatient Department No. 1
Efimova K.A.
Municipal Clinical Hospital No. 2, Outpatient Department No. 1
Kanafin E.V.
South Ural State University (SRU) — Institute of Natural and Precise Sciences
Kirilik E.V.
Polyclinic No 1 of the City Clinical Hospital No. 2
Lukyanova K.O.
Municipal Clinical Hospital No. 2, Outpatient Department No. 1
Received:
17.08.2022
Accepted:
08.09.2022
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.